A rigorous cost-benefit assessment can help to chart a cost-effective path forward.
James P. Catania
Advertisement
James P. Catania is a managing consultant at Tunnell Consulting
Articles by James P. Catania
Executive management leadership is essential in the effective implementation of QbD.
By identifying and eliminating non-value-added activities, drug manufacturers can avoid falling into the same cost-traps in the future.
Advertisement
Latest Updated Articles
Quality by Design: The Case for Change (Part II)Published: May 1st 2011 | Updated:
Quality by Design: The Case for ChangePublished: March 1st 2011 | Updated:
How to Reduce Unnecessary Compliance CostsPublished: July 1st 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
4
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
5
